MedTrace Logo

Safety Study of PRLX 93936 in Patients With Advanced Solid Tumors

NCT00528047 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2012-01-05

No results posted yet for this study

Summary

The purpose of this study is to test the safety of PRLX 93936 and see what kind of effect it has on patients and their cancer. This study will also determine the highest dose of PRLX 93936 that can be given without causing adverse side effects and the dose of PRLX 93936 that should be used in future studies.

Conditions

Interventions

DRUG

PRLX 93936

PRLX 93936 will be administered intravenously over one hour daily for 5 days.

Sponsors & Collaborators

  • Prolexys Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Daniel Von Hoff, M.D. · TGen Clinical Research Services at Scottsdale Healthcare

  • Peter J. Rosen, M.D. · Tower Cancer Research Foundation

  • Andrew Wagner, M.D., Ph.D. · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2011-03-31
Completion
2011-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00528047 on ClinicalTrials.gov